Comparison of the steady-state pharmacokinetics, metabolism, and variability of a transdermal testosterone patch versus a transdermal testosterone gel in hypogonadal men

Journal of Sexual Medicine

Volumn 2, Issue 2, 2005, Pages 213-226

  Mazer, Norman ^a,d,e   Bell, Damon ^a   Wu, Jingyang ^a   Fischer, Jerome ^b   Cosgrove, Michael ^b   Eilers, Barbara ^c  

^a Watson Pharmaceuticals Inc   (United States)

^b Diabetes and Glandular Disease Research Center   (United States)

^c Clinical Research Services   (United States)

^d UNIVERSITY OF UTAH   (United States)

^e Department of Pharmaceuticals ^*  (United States)

Author keywords

Male design methodology of clinical trials; Male sex steroid replacement; Male topical treatment

Indexed keywords

ANDROSTANOLONE; ESTRADIOL; TESTOSTERONE;

ADULT; AGED; ANALYSIS OF VARIANCE; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CIRCADIAN RHYTHM; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG METABOLISM; DRUG TOLERABILITY; GEL; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; MALE; PRIORITY JOURNAL; STEADY STATE; TRANSDERMAL PATCH;

EID: 16344390576     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2005.20231.x     Document Type: Article

References (35)

1. Electronic Orange Book, FDA Approval History of Testoderm®. http://www.accessdata.fda.gov/scripts/cder/ob/docs/ obdetail.cfm?Appl_NO=019762&TABLE1=OB_Rx
2. Electronic Orange Book, FDA Approval History of Androderm®. http://www.accessdata.fda.gov/scripts/cder/ob/docs/ obdetail.cfm?Appl_No=020489&TABLE1=OB_Rx
3. Electronic Orange Book, FDA Approval History of Testoderm® TTS. http://www.accessdata.fda.gov/scripts/cder/ob/docs/ obdetail.cfm?Appl_No=020791&TABLE1=OB_Rx
4. Electronic Orange Book, FDA Approval History of AndroGel®. http://www.accessdata.fda.gov/scripts/cder/ob/docs/ obdetail.cfm?Appl_NO=021015&TABLE1=OB_Rx
5. Electronic Orange Book, FDA Approval History of Testim®. http://www.accessdata.fda.gov/scripts/cder/ob/docs/ obdetail.cftm?Appl_NO=021454&TABLE1=OB_Rx
6. Electronic Orange Book, FDA Approval History of Striant®. http://www.accessdata.fda.gov/scripts/cder/ob/docs/ obdetail.cfm?Appl_NO=021543&TABLE1=OB_Rx.
7. Mazer NA, Heiber WE, Moellmer JF, Meikle AW, Stringham JD, Sanders SW, Tolman KG, Odell WD. Enhanced transdermal delivery of testosterone: A new physiological approach for androgen replacement in hypogonadal men. J Control Release 1992;19:346-62.
8. Caramelli KE, Mazer NA. Androderm® produces significantly higher testosterone levels than Testoderm® TTS: A comparative pharmacokinetic study in hypogonadal men. Abstract P2-475. 83rd Annual Meeting of the Endocrine Society, Denver, CO, June 2001.
9. Swerdloff RS, Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Longstreth J, Berman N. Long-term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J Clin Endocrinol Metab 2000;85:4500-10.
10. Steidle C, Schwartz S, Jacoby K, Sebree T, Smith T, Bachand R, North American AA2500 T Gel Study Group. AA2500 testosterone gel normalizes androgen levels in aging males with improvements in body composition and sexual function. J Clin Endocrinol Metab 2003;88:2673-81.
11. Androderm® Testosterone Transdermal System CIII, Prescribing Information, Physicians Desk Reference. 57th edition. Montvale, NJ: Thomson PDR; 2003:3280-2.
12. Liu JP. Use of the repeated cross-over designs in assessing bioequivalence. Stat Med 1995;14:1067-78; discussion 1079-80.
13. Meikle AW, Arver S, Dobs AS, Sanders SW, Rajaram L, Mazer NA. Pharmacokinetics and metabolism of a permeation-enhanced testosterone transdermal system in hypogonadal men: Influence of application site - A clinical research center study. J Clin Endocrinol Metab 1996;81:1832-40.
14. Miller K, Corcoran C, Armstrong C, Caramelli K, Anderson E, Cotton D, Basgoz N, Hirschhorn L, Tuomala R, Schoenfeld D, Daugherty C, Mazer N, Grinspoon S. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study. J Clin Endocrinol Metab 1998;83:2717-25.
15. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:3666-72.
16. Esoterix expected values. http://www.esoterix.com/ files/expected_values.pdf.
17. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for industry: Statistical approaches to establishing bioequivalence. January 2001.
18. Arver S, Dobs AS, Meikle AW, Caramelli KE, Rajaram L, Sanders SW, Mazer NA. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin Endocrinol (Oxf) 1997;47:727-37.
19. Dobs AS, Meikle AW, Arver S, Sanders SW, Caramelli KE, Mazer NA. Pharmacokinetics, efficacy, and safety of a permeation-enhanced testosterone transdermal system in comparison with bi-weekly injections of testosterone enanthate for the treatment of hypogonadal men. J Clin Endocrinol Metab 1999;84:3469-78.
20. Wang C, Berman N, Longstreth JA, Chuapoco B, Hull L, Steiner B, Faulkner S, Dudley RE, Swerdloff RS. Pharmacokinetics of transdermal testosterone gel in hypogonadal men: Application of gel at one site versus four sites: A General Clinical Research Center Study. J Clin Endocrinol Metab 2000;85:964-9.
21. Bae AI, Wang C, Berman N, Swerdloff RS. The effects of showering on serum testosterone levels after the application of transdermal testosterone gel. J Invest Med 2001;49:17A.
22. Wang C, Cunningham G, Dobs A, Iranmanesh A, Matsumoto AM, Snyder PJ, Weber T, Berman N, Hull L, Swerdloff RS. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. J Clin Endocrinol Metab 2004;89:2085-98.
23. Pope HG Jr, Cohane GH, Kanayama G, Siegel AJ, Hudson JI. Testosterone gel supplementation for men with refractory depression: A randomized, placebo-controlled trial. Am J Psychiatry 2003;160: 105-11.
24. Rohr UD, Saeger-Lorenz K. 17beta-estradiol matrixpatch removal and reapplication in post-menopausal women: Theoretical predictions with an oscillating diffusion coefficient model. J Pharm Sci 2002;91:822-44.
25. Azziz R, Carmina E, Sawaya ME. Idiopathic hirsutism. Endocr Rev 2000;21:347-62.
26. Lookingbill DP, Egan N, Santen RJ, Demers LM. Correlation of serum 3 alpha-androstanediol glucuronide with acne and chest hair density in men. J Clin Endocrinol Metab 1988;67:986-91.
27. Liu P, Higuchi WI, Song WQ, Kurihara-Bergstrom T, Good WR. Quantitative evaluation of ethanol effects on diffusion and metabolism of beta-estradiol in hairless mouse skin. Pharm Res 1991;8:865-72.
28. Liang T, Liao S. Inhibition of steroid 5 alpha-reductase by specific aliphatic unsaturated fatty acids. Biochem J 1992;285(Part 2):557-62.
29. Svenstrup B, Brunner N, Dombernowsky P, Nohr I, Micic S, Bennett P, Spang-Thomsen M. Comparison of the effect of cortisol on aromatase activity and androgen metabolism in two human fibroblast cell lines derived from the same individual. J Steroid Biochem 1990;35:679-87.
30. Carson C 3rd, Rittmaster R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 2003;61(4 Suppl 1):2-7.
31. Kampa M, Papakonstanti EA, Hatzoglou A, Stathopoulos EN, Stournaras C, Castanas E. The human prostate cancer cell line LNCaP bears functional membrane testosterone receptors that increase PSA secretion and modify actin cyto-skeleton. FASEB J 2002;16:1429-31 (Epub 2002 July 18).
32. Farnsworth WE. The androgen receptor of the prostate plasma membrane - An hypothesis. Med Hypotheses 2004;62:954-7.
33. Stathopoulos EN, Dambaki C, Kampa M, Theodoropoulos PA, Anezinis P, Delakas D, Delides GS, Castanas E. Membrane androgen binding sites are preferentially expressed in human prostate carcinoma cells. BMC Clin Pathol 2003;3:1-9.
34. Diver MJ, Imtiaz KE, Ahmad AM, Vora JP, Fraser WD. Diurnal rhythms of serum total, free and bioavailable testosterone and of SHBG in middle-aged men compared with those in young men. Clin Endocrinol (Oxf) 2003;58:710-7.
35. AndroGel® 1% Testosterone Gel CIII, Prescribing Information, Physicians Desk Reference. 57th edition. Montvale, NJ: Thomson PDR; 2001:3230-2.